RNA Meets Cell Therapy, and Texas Is Holding the Handshake

Cellipont and Soter Bio launch an integrated US platform linking GMP RNA production to cell therapy manufacturing

31 Mar 2026

A persistent bottleneck in advanced therapy development just found a workaround. Cellipont Bioservices and Soter Bio have announced a strategic partnership that connects GMP RNA production directly to GMP cell therapy manufacturing, creating one of the first end-to-end, US-based pipelines for mRNA-enabled cell therapies.

Announced February 24, 2026, the deal pairs Soter Bio's RNA and lipid nanoparticle expertise with Cellipont's established cell therapy CDMO infrastructure. Together, the two Houston-area companies span the full development arc: RNA drug substance, LNP formulation, cell therapy production, analytical testing, and regulatory execution.

The integration solves a real coordination problem. Developers of RNA-enabled cell therapies have historically juggled separate RNA suppliers and cell therapy manufacturers, a fragmented model that introduced delays, quality mismatches, and supply chain fragility. A single, coordinated US platform collapses that complexity, giving sponsors a cleaner path from biomolecule input to clinical-grade output.

The domestic angle matters too. Soter Bio was built to reshore advanced RNA and API manufacturing to the United States. Its Houston facility runs closed, automated, GMP-compliant production systems aligned with national biosecurity priorities. Cellipont's operations in The Woodlands add cell therapy depth and the regulatory infrastructure programs need to move toward clinical trials.

Both executives were candid about why the timing is right. Cellipont CEO Darren Head said early manufacturing alignment is critical to de-risking development and compressing clinical timelines. Soter Bio founder and CEO Mike Stewart cited the need for reliable, scalable upstream inputs as the foundation of any successful advanced therapy program.

The collaboration covers investigational cell therapies, RNA platform technologies, and government-sponsored public health programs. As the US pipeline of RNA-enabled and mRNA-instructed cell therapies matures toward clinical and commercial stages, integrated manufacturing is shifting from competitive advantage to table stakes. This partnership positions two Texas-based companies, and by extension the broader US manufacturing base, at the center of that shift.